Success Stories: NIW Approved for Computational and Mathematical Engineering Researcher Advancing Computational Immunology

Client’s Testimonial:

“Thank you for helping file the I-140 successfully!! You were very clear in what I needed to do, and timely in your processing.”

On August 5^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Data Scientist in the field of Computational and Mathematical Engineering (Approval Notice).

General Field: Computational and Mathematical Engineering

Position at the Time of Case Filing: Senior Data Scientist

Country of Origin: India

State of Residence at the Time of Filing: California

Approval Notice Date: August 5^th, 2025

Processing Time: 1 month, 16 days (Premium Processing Requested)

Case Summary:

We are pleased to share the success story of a National Interest Waiver approval for a researcher whose expertise in computational immunology and machine-learning–driven biomarker discovery promises to enhance diagnostic accuracy and patient outcomes. By developing efficient algorithms to analyze high-dimensional immune data, the client addresses urgent national needs in disease surveillance and precision medicine.

Research Focus and Contributions

The petition described the client’s proposed endeavor to design and implement computational frameworks that:

Extract epigenetic and transcriptomic patterns from single-cell immune datasets to reveal disease-associated signatures.
Interpret complex machine-learning models via network-based feature analysis to improve explainability in clinical decision-support tools.
Optimize foundation-model tokenization and input design for robust classification of immunological disease states.
Develop data-driven methods to link genetic risk factors with severe infection outcomes, guiding targeted intervention strategies.

Research Impact and Metrics

To demonstrate substantial merit and national importance, the petition assembled key quantitative metrics:

7 journal articles and 2 first-authored conference abstracts, plus 2 preprints.
29 citations, including two papers ranking in the top citation percentiles for their publication years.
Completed at least 11 invited manuscript reviews for leading journals, confirming recognized expertise.

Demonstrating Substantial Merit & National Importance

The petition highlighted how the client’s algorithms reduce misdiagnosis rates, which account for nearly 16% of preventable patient harm, and enable the earlier detection of autoimmune and infectious diseases, thereby easing healthcare burdens and improving public safety. Funded by NIAID and the Bill & Melinda Gates Foundation, this research directly advances U.S. priorities in precision health and pandemic preparedness.

Well Positioned to Advance the Proposed Endeavor

Equipped with a Ph.D. in Computational and Mathematical Engineering and currently serving as a Senior Data Scientist at a leading U.S. research institution, the client has a proven record of cross-disciplinary collaboration and successfully translating computational tools into clinical studies. Expert recommendation letters emphasize the client’s ability to bridge advanced algorithm design and real-world healthcare applications.

NIW Approval and Outlook

Filed on June 20, 2025, with premium processing, and approved on August 5, 2025, in just 1 month and 16 days, this NIW approval underscores the critical impact of computational innovations in U.S. health care. We look forward to supporting the client’s ongoing work in developing next-generation diagnostic algorithms that will strengthen national disease surveillance and improve patient outcomes across the country.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.